U-Screen Dx Overview

  • Founded
  • 2013
  • Status
  • Out of Business
  • Employees
  • 4
  • Latest Deal Type
  • Out of Business

U-Screen Dx General Information


Developer of cancer screening tests designed to detect cancer in the early stage. The company's tests is an early-stage biotech enterprise developing screening tests focused on infection-related cancers such as hepatitis B virus (HBV)-induced liver cancer, enabling doctors to accurately and simultaneously detect both genetic and epigenetic circulating DNA markers in urine and blood.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Healthcare Technology Systems
Primary Office
  • 3805 Old Easton Road
  • Doylestown, PA 18902
  • United States
+1 (484) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

U-Screen Dx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 28-Nov-2020 Completed Out of Business
2. Grant 01-Jan-2015 00000 Completed Generating Revenue
1. Accelerator/Incubator 11-Jul-2014 Completed Generating Revenue
To view U-Screen Dx’s complete valuation and funding history, request access »

U-Screen Dx Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial